Skip to main content

First-Half 2022 Results

Marcy l’Etoile (France) – The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on August 30 under the chairmanship of Alexandre Mérieux and approved the consolidated financial statements for the six months ended June 30, 2022.

  • €1,658 million in first-half 2022 sales, up 5.3% as published,  stable on a like-for-like basis
  • Q2 sales organic growth up 5.2% like-for-like, led by a strong growth of BIOFIRE® range as well as a good performance in clinical microbiology and industry applications
  • Contributive operating income before non-recurring items reached  €322 million, or 19.4% of sales for the first half of the year
  • 2022 guidance slightly improved
  • bioMérieux strengthens its commitment to fight antimicrobial resistance with the acquisition of Specific Diagnostics
  • Reinforced portfolio of solutions with new product launches 

Alexandre Mérieux, Chairman and Chief Executive Officer, said: “bioMérieux achieved a solid performance in the first half of 2022, in line with its  expectations, both in terms of top line and profitability.  In addition, we made a major acquisition in the field of rapid antimicrobial susceptibility testing with Specific Diagnostics that reinforces our long-standing commitment to sustain antibiotic efficacy for future generations and fits perfectly with our existing solutions. Within a highly uncertain and inflationary environment, we do confirm our annual guidance, slightly adjusted upward.

Read the full press release

PR_bioMérieux_Financial_Results_H1 2022.pdf
365 KB